21
total announcements
539872.BO · 15 min delayed
Bajaj Healthcare Ltd
Bajaj Healthcare Ltd has received approval from the Hon'ble National Company Law Tribunal (NCLT) for the acquisition of Genrx Pharmaceuticals Private Limited on a going concern basis.
Bajaj Healthcare Ltd
Bajaj Healthcare Ltd has scheduled an earnings call to discuss its financial performance for Q2 & H1 FY27 on October 19, 2026.
Bajaj Healthcare Ltd
Bajaj Healthcare Ltd has disclosed the sale of a business unit to Spa Vet Private Limited and Indosol Pure Technologies Private Limited for Rs. 14.67 Crores. The transaction does not involve related parties and the trading window remains closed for designated persons.
Bajaj Healthcare Ltd
Bajaj Healthcare Ltd has scheduled a Board Meeting on October 17, 2026, to consider and approve the un-audited financial results for the quarter and half year ended September 30, 2026.
Bajaj Healthcare Ltd
Bajaj Healthcare Ltd has received a compliance certificate from its registrar and share transfer agent, MUFG Intime India Private Limited, under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026.
Bajaj Healthcare Ltd
Bajaj Healthcare Ltd has announced the closure of its trading window for all designated persons, including their immediate relatives, from October 1, 2026, until 48 hours after the declaration of its un-audited financial results for the quarter and half year ended September 30, 2026.
Bajaj Healthcare Ltd
Bajaj Healthcare Ltd has submitted the voting results and scrutinizer's report for its 33rd Annual General Meeting (AGM), which was held on September 21, 2026. The company has announced the approval of six resolutions, including the declaration of a final dividend of Rs. 1.50 per equity share for the financial year ended March 2026.
Bajaj Healthcare Ltd
Bajaj Healthcare Ltd has announced the record date for the payment of a final dividend of 30% for the financial year 2025-26, to be paid to shareholders as on September 14, 2026, if declared and approved at the upcoming Annual General Meeting.
Bajaj Healthcare Ltd
Bajaj Healthcare Ltd has announced the dispatch of notice of 33rd Annual General Meeting and Annual Report for the financial year 2025-26, as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Bajaj Healthcare Ltd
Bajaj Healthcare Ltd has dispatched a letter to shareholders who have not registered their email addresses, providing a web-link to access the Annual Report 2025-26. The company also reminds shareholders to update their KYC details and dematerialize physical securities.
Bajaj Healthcare Ltd
Bajaj Healthcare Ltd has released its Business Responsibility and Sustainability Report for the financial year 2025-26, as per SEBI regulations.
Bajaj Healthcare Ltd
Bajaj Healthcare Ltd has announced the dispatch of its Annual Report for the financial year 2025-26 and scheduled its 33rd Annual General Meeting for September 21, 2026.
Bajaj Healthcare Ltd
Bajaj Healthcare Ltd has announced its 33rd Annual General Meeting (AGM) to be held on September 21, 2026, through video conferencing. The company has also dispatched its Annual Report for the financial year 2025-26 to shareholders.
Bajaj Healthcare Ltd
Bajaj Healthcare Ltd has announced the 33rd Annual General Meeting (AGM) to be held on September 21, 2026, through Video Conferencing (VC) or Other Audio Visual Means (OAVM). The company has also published a notice regarding the compulsory transfer of equity shares to the Investor Education and Protection Fund (IEPF) due to unpaid dividend for seven consecutive years or more.
Bajaj Healthcare Ltd
Bajaj Healthcare Ltd has allotted 2,500 equity shares to eligible employees under the Bajaj Healthcare Limited Employee Stock Option Scheme 2024, following the exercise of 2,500 vested stock options at an exercise price of ₹5 per stock option.
Bajaj Healthcare Ltd
Bajaj Healthcare Ltd has received approval from the Drug Controller General of India (DCGI) to manufacture and market Cenobamate API and Tablets in six strengths, making it the first company to launch Cenobamate in India.
Bajaj Healthcare Ltd
Bajaj Healthcare Ltd's bank loan facilities have been upgraded to 'IND A' with a stable outlook and 'IND A1' for short-term facilities by India Ratings and Research (Ind-Ra) due to the company's strengthened business and operational profile, marked by healthy order visibility and sustained gross margins.
Bajaj Healthcare Ltd
Bajaj Healthcare Ltd has announced the transcript of its Q1FY27 earnings call, highlighting its strategic focus on API and formulation businesses, including expansion into high-value science-led APIs and oncology APIs, and strengthening its formulation business through the acquisition of GenRx Pharmaceutical manufacturing facility.
Bajaj Healthcare Ltd
Bajaj Healthcare Ltd has published its un-audited financial results for the quarter ended June 30, 2026, in compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Bajaj Healthcare Ltd
Bajaj Healthcare Ltd has uploaded the audio recording of its Q1FY27 earnings call on its website.